If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX(1-800-545-5979)
Tirzepatide
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Tirzepatide: Comparison With Once-Weekly Semaglutide 2 mg
Tirzepatide compared with semaglutide 2 mg has not been studied.
cFAQ
cFAQ
US_cFAQ_TZP306_SEMAGLUTIDE_2MG
en-US
Detailed Information
SURPASS-2 compared tirzepatide with once-weekly semaglutide 1 mg, the highest approved dose of semaglutide available at the time.1,2
Lilly has not conducted and are not currently conducting clinical studies comparing tirzepatide with once-weekly semaglutide 2 mg.2
References
1A study of tirzepatide (LY3298176) versus semaglutide once weekly as add-on therapy to metformin in participants with type 2 diabetes (SURPASS-2). ClinicalTrials.gov identifier: NCT03987919. Updated March 11, 2021. Accessed March 23, 2021. https://clinicaltrials.gov/ct2/show/NCT03987919
2Data on file, Eli Lilly and Company and/or one of its subsidiaries.
Glossary
Lilly = Eli Lilly and Company
Date of Last Review: March 23, 2021
Contact Lilly
Call Us
If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.
Available Mon - Fri, 9am - 7pm EST